Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?

Cancer chemotherapy and pharmacology - 1 Dec 2009

Zampino Maria Giulia, Magni Elena, Sonzogni Angelica, Renne Giuseppe

Abstract excerpt

PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours. SCC is now considered the prototype for the successful application of conservative treatment as chemoradiation instead of aggressive surgery. The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated. The purpose of our evaluation was to give information about this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anus Neoplasms
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Drug Delivery Systems

Share to ErbB Receptors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19727729
DOI: 10.1007/s00280-009-1117-3

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?PMID 19727729Read ↗

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?Semantic proximity Read ↗

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.Semantic proximity Read ↗

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.Semantic proximity Read ↗

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.Semantic proximity Read ↗

p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.Semantic proximity Read ↗

Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinomaSemantic proximity Read ↗

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.Semantic proximity Read ↗

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.Semantic proximity Read ↗

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.Semantic proximity Read ↗

KRAS and BRAF mutations in anal carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.